Background & Aims: A better understanding of the immunomodulatory effects of PegIFNa therapy could allow more rational optimisation of future therapeutic approaches in chronic HBV infection. In this study, we evaluated dynamic changes in the innate and adaptive arms of the immune system induced by PegIFNa. Methods: PBMC were obtained from a cohort of patients with eAg-negative CHB before, during and after PegIFNa treatment. The number, phenotype and function of global and virus-specific T cells and NK cells were analyzed by flow cytometry and serum cytokines by ELISA or CBA. Results: The absolute number of CD8 T cells was strikingly reduced on PegIFNa therapy (p <0.001), with a predominant loss of end-stage effectors, including CMV-specific CD8 T cells. There was no significant recovery of the exhausted HBV-specific CD8 T cell response. By contrast, PegIFNa was able to potently and cumulatively drive the proliferation and expansion in absolute numbers of CD56bright NK cell numbers (p <0.001), with induction of the pro-proliferative cytokine IL-15. Expanded CD56bright NK cells showed enhanced expression of activation markers and the activating receptor NKp46, accompanied by augmentation of TRAIL and IFN-c expression (p <0.001). Peak virological response (temporal within individual patients and crosssectional within the cohort) correlated with the degree of expansion of functional CD56bright NK cells. Conclusions: IFN-a mediates divergent effects on the innate and adaptive arms of the immune system in vivo. The efficacy of Peg- IFNa may be limited by its depleting effect on CD8 T cells; conversely, it can cumulatively drive proliferation, activation and antiviral potential of CD56bright NK cells.

Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B / Micco, L; Peppa, D; Loggi, E; Schurich, A; Jefferson, L; Cursaro, C; Panno, Am; Bernardi, M; Brander, C; Bihl, F; Andreone, P; Maini, Mk.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 58:2(2013), pp. 225-233. [10.1016/j.jhep.2012.09.029]

Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B

Bernardi M;Andreone P;
2013

Abstract

Background & Aims: A better understanding of the immunomodulatory effects of PegIFNa therapy could allow more rational optimisation of future therapeutic approaches in chronic HBV infection. In this study, we evaluated dynamic changes in the innate and adaptive arms of the immune system induced by PegIFNa. Methods: PBMC were obtained from a cohort of patients with eAg-negative CHB before, during and after PegIFNa treatment. The number, phenotype and function of global and virus-specific T cells and NK cells were analyzed by flow cytometry and serum cytokines by ELISA or CBA. Results: The absolute number of CD8 T cells was strikingly reduced on PegIFNa therapy (p <0.001), with a predominant loss of end-stage effectors, including CMV-specific CD8 T cells. There was no significant recovery of the exhausted HBV-specific CD8 T cell response. By contrast, PegIFNa was able to potently and cumulatively drive the proliferation and expansion in absolute numbers of CD56bright NK cell numbers (p <0.001), with induction of the pro-proliferative cytokine IL-15. Expanded CD56bright NK cells showed enhanced expression of activation markers and the activating receptor NKp46, accompanied by augmentation of TRAIL and IFN-c expression (p <0.001). Peak virological response (temporal within individual patients and crosssectional within the cohort) correlated with the degree of expansion of functional CD56bright NK cells. Conclusions: IFN-a mediates divergent effects on the innate and adaptive arms of the immune system in vivo. The efficacy of Peg- IFNa may be limited by its depleting effect on CD8 T cells; conversely, it can cumulatively drive proliferation, activation and antiviral potential of CD56bright NK cells.
2013
58
2
225
233
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B / Micco, L; Peppa, D; Loggi, E; Schurich, A; Jefferson, L; Cursaro, C; Panno, Am; Bernardi, M; Brander, C; Bihl, F; Andreone, P; Maini, Mk.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 58:2(2013), pp. 225-233. [10.1016/j.jhep.2012.09.029]
Micco, L; Peppa, D; Loggi, E; Schurich, A; Jefferson, L; Cursaro, C; Panno, Am; Bernardi, M; Brander, C; Bihl, F; Andreone, P; Maini, Mk.
File in questo prodotto:
File Dimensione Formato  
Antiviral responses.pdf

Accesso riservato

Dimensione 916.27 kB
Formato Adobe PDF
916.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237220
Citazioni
  • ???jsp.display-item.citation.pmc??? 90
  • Scopus 205
  • ???jsp.display-item.citation.isi??? 191
social impact